Introduction
Acute myelocytic leukemia (AML) and myelodysplastic syndromes (MDS) are diseases that are more prevalent in the elderly. The median age at diagnosis, according to Surveillance, Epidemiology, and End Results (SEER) statistics, is 68 years. Results with chemotherapy, even though it might be successful in inducing a first remission, have been poor, and only a few patients above the age of 55 years have become long-term survivors. Treatment with conventional allogeneic hematopoietic cell transplantation (HCT) has been limited to younger patients because high-dose cytotoxic conditioning regimens are poorly tolerated by the elderly. In order to address a clear need for alternative therapies in older patients, recent years have seen the introduction of various reduced-intensity and non-myeloablative conditioning regimens for allogeneic HCT. The principles of this approach included the reduction of regimenrelated toxicities and shifting the burden of tumor cell kill from high-dose cytotoxic therapy to graft-versusleukemia effects. The following report reviews recent results with this approach in patients with AML/MDS.
One study in patients with AML and MDS conducted at M.D. Anderson Cancer Center used two conditioning regimens, one consisting of fludarabine, Ara-C and idarubicin, idarubicin (FAI), whereas the other combined fludarabine with melphalan (FM) either at 140 or 180 mg/m 2 [1] . The median ages of patients given the FAI and FM regimens were 61 and 54 years, respectively. Forty-four per cent of FAI patients were in remission at HCT compared with 16% of FM patients. All FAI patients had sibling donors, whereas 47% of FM patients had unrelated donors. Three-year non-relapse mortality for FAI patients was 16% compared with 39% for FM patients, relapse rates were 53% and 26%, and 3-year event-free survival rates were 31% and 35%, respectively.
A UK MDS/AML study included 76 patients conditioned with FM 140 mg/m 2 and alemtuzumab [2] . Two-year survival rates for AML patients in first, second, or third remissions ranged from 40% to 45%, MDS patients had a 35% survival, and patients with relapsed/refractory disease had a survival of approximately 30%.
A study from the Dana-Farber Cancer Center in patients with myeloid malignancies compared high-dose regimens, either cyclophosphamide and fractionated total body irradiation or busulfan 16 mg/kg, and cyclophosphamide, to a reduced-intensity regimen of fludarabine and busulfan 3.2 mg/kg [3] . Follow-up was considerably shorter for reduced-intensity patients. The 2-year transplant-related mortality for reduced-intensity patients was 30% compared with 45% for high-dose patients. In turn, the relapse rate for high-dose regimens was 25%
The development of non-myeloablative and reduced-intensity conditioning regimens has enabled older or medically infirm patients with myeloid malignancies to be treated with allogeneic hematopoietic cell transplantation (HCT). The regimens are sufficiently immunosuppressive to allow engraftment of allogeneic cells and they rely largely on graft-versus-leukemia effects rather than high-dose cytotoxic therapy to eliminate malignant cells. Overall 2-5-year survivals after allogeneic HCT in older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) have ranged from 25% to 64%. Outcomes were comparable for human leukocyte antigen-matched related and unrelated grafts. The best results were seen in patients transplanted in the first or second remission. Relapse and progressive disease continue to be problems, particularly in patients with large tumor burdens at the time of HCT. Reduction of the tumor burden before HCT with targeted therapy such as radiolabelled anti-CD45 antibody may improve the outcome. Despite still existing problems, early results in elderly patients with AML/MDS have been encouraging.
Keywords acute myelocytic leukemia, allogeneic hematopoietic cell transplantation, graft-versusleukemia effects, myelodysplastic syndrome, reduced-intensity conditioning compared with 35% for the reduced-intensity regimen. Accordingly, 2-year survivals for the two treatment modalities were comparable, approximately 30% for high-dose regimens and 35% for the reduced-intensity regimen.
Five of the following six studies were presented at the American Society of Hematology meeting in December of 2008.
A large Center for International Blood and Marrow Transplant Research (CIBMTR) study analyzed results with reduced-intensity conditioning and either related or unrelated grafts in patients with AML and MDS in a first complete response (CR1) [4] . Four groups of patients were studied, aged either 40-45, 55-60, 60-64, or older than 65 years (including 220, 150, 132 and 63 patients, respectively). One-year non-relapse mortalities among the four age groups ranged from 18% to 30% for AML patients and from 31% to 34% for MDS patients. The 3-year relapse mortalities ranged from 29% to 39% for both disease categories across all age groups.
Three-year progression-free survival rates for the four AML patient groups were 43%, 41%, 27% and 34%, and for the four MDS groups 36%, 27%, 29% and 23%, respectively.
Another CIBMTR analysis studied 3731 myeloablative patients with AML/MDS and a median age of 42 years and 1500 reduced-intensity/non-myeloablative patients with a median age of 55 years [5] . The longest follow-up for myeloablative patients was 58 months compared with 40 months for reduced-intensity/nonmyeloablative patients. Non-relapse mortalities were 34% for myeloablative and 34-37% for reducedintensity/non-myeloablative patients. Relapse rates were 32% for myeloablative and 39-43% for reducedintensity/non-myeloablative patients. Event-free survivals were 33% for myeloablative and 24-30% for reduced-intensity/non-myeloablative patients.
A French multicenter study focused on 2-year survivals in patients with AML in first remission who were given human leukocyte antigen (HLA)-identical sibling grafts [6] . Their median age was 55 years, and multiple reduced-intensity regimens were used. Twenty-one patients with good cytogenetic risk had 64% survival, 304 patients with intermediate-risk cytogenetics had 57% survival, and 53 patients with poor-risk cytogenetics had 38% survival.
A German multicenter study analyzed results in 172 patients with AML/MDS with poor-risk cytogenetics [7] . The median patient age was 53 years. Conditioning consisted of a fludarabine, AraC, Amsa reduced-intensity regimen. Related and unrelated donors were used.
Seventeen percent of patients were treated up front without preceding chemotherapy, 33% had primary induction failure, 22% were in CR1 and 28% were in relapse. The overall 4-year relapse rate was 30%, nonrelapse mortality was 21% and event-free survival was 32%.
Another German AML study analyzed 3-year survivals in 103 patients with AML given myeloablative regimens and 265 given reduced-intensity regimens [8] . The median patient age was 57 years. Among patients with standard-risk cytogenetics and transplanted in first remission, survival for HLA-matched sibling recipients was 60% compared with 45-50% for unrelated recipients. In patients with standard-risk cytogenetics transplanted in 1st remission, survivals both among unrelated and related recipients were 20%. Among patients in first remission with high-risk abnormalities, survival after unrelated grafts was 40% compared with 30% after HLA-matched sibling grafts. High-risk sibling recipients transplanted in >CR1 had an approximately 5% survival compared with 20% for unrelated recipients.
A multicenter study from the Seattle Consortium included 259 patients with a median age of 59 years who either had de novo AML in first (n ¼ 95) or second (n ¼ 57) remission, were not in CR1 or second complete remission (CR2; n ¼ 26), or had secondary AML (n ¼ 81) [9] . A total of 112 patients had HLA-identical sibling donors, 116 had HLA-matched unrelated donors and 31 had HLA-mismatched donors (unrelated n ¼ 30). Fiveyear outcomes were evaluated. Ninety-six percent of patients had durable engraftment following a truly non-myeloablative conditioning regimen of fludarabine, 30 mg/m 2 per day for 3 days and 2 Gy of total body irradiation. All patients received postgrafting immunosuppression with mycophenolate mofetil and either cyclosporine or FK506. Non-relapse mortality, which was significantly influenced by co-morbidities, was 25% for patients in CR1, 27% for those in CR2, 35% for those not in CR1 or CR2 and 28% for those with secondary AML. Relapse mortalities for the four patient groups were 36%, 36%, 42% and 46%, respectively. When analyzing results by origin of hematopoietic cell grafts, non-relapse mortality was 18% among patients with HLA-matched sibling donors, 31% among those with HLA-matched unrelated donors and 55% among those with HLA-mismatched donors. No statistically significant differences in non-relapse mortalities were seen among patients aged 60-64 (n ¼ 166; 28%), 65-69 (n ¼ 90; 22%) and 70-74 (n ¼ 24; 29%) years. Among patients with AML in CR1, those with minimal residual disease at HCT, detected either by flow cytometry, cytogenetics or molecular probes, had significantly increased relapse mortality in multivariate analysis with a hazard ration of 4.60 (P ¼ 0.007). Survivals of patients S4 Reduced-intensity conditioning for allogeneic stem cell transplantation with de-novo AML in CR1 or CR2 were 40% and approximately 25% among AML patients not in CR1 or CR2 and secondary AML patients.
Conclusion
Taken together, the available data showed 2-5-year survival rates of 25-64% after allogeneic HCT for older AML/MDS patients. Survival was similar for recipients of related and unrelated HLA-matched grafts. Major issues included non-relapse mortalities ranging from 16% to 39%, which partly resulted from complications of graft-versus-host disease including infections and were partly caused by co-morbidities preceding HCT. Relapse rates ranged from 16% to 53%, and were influenced both by disease burden and cytogenetic risk at HCT. Attempts to reduce relapse have included targeted antileukemic therapy added to conditioning regimens, such as radiolabelled monoclonal antibody directed at CD45. Future work focuses on gaining a better understanding of minor histocompatibility antigen disparities between donors and recipients, which might help in distinguishing between targets of adverse immunological reactions, such as graft-versus-host disease, and beneficial graft-versusleukemia effects. Nevertheless, despite still existing problems, the outcomes of allogeneic HCT in older AML/MDS patients have been encouraging, especially in those who were transplanted beyond first remission.
